Praxis Precision Medicines | 10-Q: Quarterly report

SEC announcementMay 13 20:24 · Announcements

Praxis Precision Medicine Says Cash And Investments Of $451.2M As Of April 30, 2024 Extends Runway Into 2027

Praxis Precision Medicine Says Cash And Investments Of $451.2M As Of April 30, 2024 Extends Runway Into 2027

BenzingaMay 13 19:14

Praxis Precision Medicines Advances Precision Therapies for CNS Disorders, Anticipates Key Milestones in Seizure and Pediatric Epilepsy Treatment

Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders cha

BenzingaMay 13 19:14

Praxis Precision Medicine Q1 2024 GAAP EPS $(2.84) Misses $(2.08) Estimate

Praxis Precision Medicine Q1 2024 GAAP EPS $(2.84) Misses $(2.08) Estimate

BenzingaMay 13 19:13

Praxis Precision Med 2Q Loss/Shr $2.84 >PRAX

Praxis Precision Med 2Q Loss/Shr $2.84 >PRAX

Dow JonesMay 13 19:01

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous

GlobeNewswireMay 10 20:00